TBPH
NASDAQTheravance Biopharma Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks31+25%
2025-12-072026-05-31
Mix2090d
- Insider10(50%)
- SEC Filings6(30%)
- Earnings2(10%)
- Analyst1(5%)
- Other1(5%)
Latest news
25 items- INSIDERCHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 20,038 units of Ordinary Shares, decreasing direct ownership by 1% to 1,631,056 units (SEC Form 4) to cover withholding tax4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERSVP & CHIEF FINANCIAL OFFICER Sawaf Aziz covered exercise/tax liability with 8,670 units of Ordinary Shares, decreasing direct ownership by 2% to 344,953 units (SEC Form 4) (withholding obligation)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERSVP, DEV & HEAD OF IRE OFFICE Miller Aine covered exercise/tax liability with 6,827 units of Ordinary Shares, decreasing direct ownership by 4% to 177,334 units (SEC Form 4) to satisfy withholding obligation4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERSVP, GEN COUNSEL AND SECRETARY Grimaud Brett A. covered exercise/tax liability with 8,829 units of Ordinary Shares, decreasing direct ownership by 2% to 363,120 units (SEC Form 4) (withholding tax)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERSVP, COMM & MEDICAL AFFAIRS Farnum Rhonda covered exercise/tax liability with 5,678 units of Ordinary Shares, decreasing direct ownership by 2% to 245,771 units (SEC Form 4) (withholding tax)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- SECSEC Form 10-Q filed by Theravance Biopharma Inc.10-Q - Theravance Biopharma, Inc. (0001583107) (Filer)
- SECTheravance Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
- PRTheravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYUPELRI® Collaboration Revenue increased 15% year-over-year1, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverageAll Hatch-Waxman litigation relating to YUPELRI® has been resolved following settlement with Mankind Pharma in MarchOrganizational restructuring and cost reduction initiatives on track; delivered ~20% reduction in Operating Expenses year-over-year (excluding restructuring items)Q1 2026 TRELEGY net sales, reported by GSK, of $873 million, up 2% year-over-year; high confidence in achieving the $100 million 2026 milestone payment2Strategic Review Committee actively evaluating a range of opportunities to maximize shareholder valueQ
- SECSEC Form DEF 14A filed by Theravance Biopharma Inc.DEF 14A - Theravance Biopharma, Inc. (0001583107) (Filer)
- INSIDERSEC Form 4 filed by Winningham Rick E4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERSEC Form 4 filed by Sawaf Aziz4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERSEC Form 4 filed by Grimaud Brett A.4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERSEC Form 4 filed by Farnum Rhonda4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- SECTheravance Biopharma Inc. filed SEC Form 8-K: Other Events8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Theravance Biopharma Inc.SCHEDULE 13D/A - Theravance Biopharma, Inc. (0001583107) (Subject)
- SECSEC Form 10-K filed by Theravance Biopharma Inc.10-K - Theravance Biopharma, Inc. (0001583107) (Filer)
- SECTheravance Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
- PRTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateOrganizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starting in Q3 2026Strategic Review Committee accelerating evaluation of opportunities to maximize shareholder valueYUPELRI® achieved record brand profitability for Q4 and full-year 2025; full-year net sales of $266.6 million, recognized by Viatris, up 12% year-over-year1 resulting in a $25 million milestone payment Full-year 2025 TRELEGY net sales, reported by GSK, of $3.9 billion, up 12% year-over-year, triggered a $50 million milestone payment; high confidence in achieving the $100 million 2026 mil
- INSIDERSEC Form 4 filed by Farnum Rhonda4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- ANALYSTTheravance Biopharma downgraded by OppenheimerOppenheimer downgraded Theravance Biopharma from Outperform to Perform
- ANALYSTTheravance Biopharma downgraded by B. Riley Securities with a new price targetB. Riley Securities downgraded Theravance Biopharma from Buy to Neutral and set a new price target of $14.00
- SECTheravance Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
- PRTheravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction ActionsPhase 3 CYPRESS study did not meet the primary endpoint, the OHSA Composite Score, a patient reported outcome (PRO)Cash of $326.5 million at Q4 2025 (no debt); approximately $400 million expected at end of Q1 2026 including receipt of 2025 milestones; Theravance highly confident in achieving $100 million 2026 TRELEGY milestone1Strategic Review Committee accelerating ongoing efforts to evaluate alternatives to maximize shareholder valueOrganizational restructuring to reduce cost base by approximately 60% (or approximately $70 million); expected to result in the Company generating approximately $60 - $70 million of annualized cash flowStreamlined portfolio focused on YUPELRI®, a growing produc
- INSIDERCHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 74,975 units of Ordinary Shares, decreasing direct ownership by 5% to 1,576,094 units (SEC Form 4)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERSVP & CHIEF FINANCIAL OFFICER Sawaf Aziz covered exercise/tax liability with 20,672 units of Ordinary Shares, decreasing direct ownership by 6% to 316,123 units (SEC Form 4)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
TBPH FAQ
6 questionsWhat does Theravance Biopharma Inc. do?
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory...Where does TBPH stock trade?
Theravance Biopharma Inc. (TBPH) is listed on NASDAQ.What sector and industry is TBPH in?
Theravance Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TBPH?
Theravance Biopharma Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Perform on 2026-03-05. Recent price targets range from $1000.00 to $2800.00.What companies are similar to TBPH?
Notable peers in the same industry include INVA (Innoviva Inc.), STRO (Sutro Biopharma Inc.), CUE (Cue Biopharma Inc.). Compare TBPH side-by-side with any of them on Quantisnow.How can I track TBPH on Quantisnow?
Quantisnow aggregates Theravance Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TBPH to receive live email and push alerts on every new disclosure.